Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, et al.
Hepatology Research (2022) Vol. 53, Iss. 2, pp. 104-115
Closed Access | Times Cited: 24

Showing 24 citing articles:

Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 6
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access | Times Cited: 5
MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 10, pp. 947-964
Open Access | Times Cited: 27
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 10, pp. 7565-7577
Closed Access | Times Cited: 25
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Harry Crane, Guy D. Eslick, Cameron Gofton, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 3, pp. 436-448
Open Access | Times Cited: 15
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 2, pp. 263-265
Open Access | Times Cited: 11
MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options
Yuming Shi, Erfan Taherifard, A.I. Saeed, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 6, pp. 5965-5983
Open Access | Times Cited: 6
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study
Tomoya Sano, Keisuke Amano, Tatsuya Ide, et al.
Hepatology Research (2023) Vol. 54, Iss. 4, pp. 326-335
Closed Access | Times Cited: 14
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
Liver Cancer (2024) Vol. 13, Iss. 5, pp. 522-536
Open Access | Times Cited: 5
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Maito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
Hepatology International (2024)
Open Access | Times Cited: 4
Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study
Takashi Nishimura, Toshifumi Tada, Tomoyuki Akita, et al.
Journal of Gastroenterology (2025)
Open Access
Metabolic-associated fatty liver disease and the risk of cardiovascular disease
Pengwei Zhang, Xianhui Dong, Wei Zhang, et al.
Clinics and Research in Hepatology and Gastroenterology (2022) Vol. 47, Iss. 1, pp. 102063-102063
Closed Access | Times Cited: 16
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases
Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, et al.
Nutrients (2023) Vol. 15, Iss. 5, pp. 1123-1123
Open Access | Times Cited: 9
Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 4, pp. 705-708
Open Access | Times Cited: 2
Treatment options for advanced hepatocellular carcinoma: the potential of biologics
Federico Rossari, Silvia Foti, S. Camera, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 6, pp. 455-470
Closed Access | Times Cited: 2
Effect of a combination of pemafibrate and a mild low‐carbohydrate diet on obese and non‐obese patients with metabolic‐associated fatty liver disease
Yuichiro Suzuki, Shinya Maekawa, Kohji YAMASHITA, et al.
Journal of Gastroenterology and Hepatology (2023) Vol. 38, Iss. 6, pp. 921-929
Open Access | Times Cited: 6
Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions
Eeda Venkateswararao, Nikhil Y. Patil, Aditya Dilip Joshi, et al.
Hepatology Research (2023) Vol. 54, Iss. 3, pp. 222-234
Closed Access | Times Cited: 4
Prevalence of Non-alcoholic Fatty Liver Disease Detected by Computed Tomography in the General Population Compared with Ultrasonography
Yuki Ito, Kentaro Yoshioka, Kazuhiko Hayashi, et al.
Internal Medicine (2023) Vol. 63, Iss. 2, pp. 159-167
Open Access | Times Cited: 3
Coincidental items in the definition of metabolic dysfunction‐associated fatty liver are useful in identifying patients having significant fibrosis with fatty liver
Keisuke Kakisaka, Hidekatsu Kuroda, Tamami Abe, et al.
Hepatology Research (2023) Vol. 53, Iss. 9, pp. 857-865
Closed Access | Times Cited: 3
Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib
Sayo Tsumura, Shigeo Shimose, Takashi Niizeki, et al.
Journal of Gastroenterology and Hepatology (2023) Vol. 38, Iss. 7, pp. 1140-1147
Closed Access | Times Cited: 2
An ever-increasing metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: what are problems and countermeasures?
Shigeo Shimose, Tsubasa Tsutsumi, Dan Nakano, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 6, pp. 941-944
Open Access | Times Cited: 2
Survival and Endoscopic/Clinical Features of Patients with Colorectal Cancer Resected by Cold Snare Polypectomy: The Importance of Chronic Kidney Disease
Tsutomu Nagata, Miwa Sakai, Michita Mukasa, et al.
The Kurume Medical Journal (2024)
Open Access
Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study
Kazuto Tajiri, Yoshiharu Tokimitsu, Kengo Kawai, et al.
Anticancer Research (2022) Vol. 42, Iss. 12, pp. 6007-6018
Open Access | Times Cited: 2
New Concept of Fatty Liver: Metabolic dysfunction-associated fatty liver disease
Takumi Kawaguchi
Kanzo (2023) Vol. 64, Iss. 2, pp. 33-43
Open Access
Page 1

Scroll to top